Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):769-777. doi: 10.1093/cid/ciaa272.
From December 2019 to February 2020, 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China. Related clinical features are needed.
We reviewed 69 patients who were hospitalized in Union hospital in Wuhan between 16 January and 29 January 2020. All patients were confirmed to be infected with SARS-CoV-2, and the final date of follow-up was 4 February 2020.
The median age of 69 enrolled patients was 42.0 years (interquartile range 35.0-62.0), and 32 patients (46%) were men. The most common symptoms were fever (60 [87%]), cough (38 [55%]), and fatigue (29 [42%]). Most patients received antiviral therapy (66 [98.5%] of 67 patients) and antibiotic therapy (66 [98.5%] of 67 patients). As of 4 February 2020, 18 (26.9%) of 67 patients had been discharged, and 5 patients had died, with a mortality rate of 7.5%. According to the lowest SpO2 during admission, cases were divided into the SpO2 ≥ 90% group (n = 55) and the SpO2 < 90% group (n = 14). All 5 deaths occurred in the SpO2 < 90% group. Compared with SpO2 ≥ 90% group, patients of the SpO2 < 90% group were older and showed more comorbidities and higher plasma levels of interleukin (IL) 6, IL10, lactate dehydrogenase, and C reactive protein. Arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate.
COVID-19 appears to show frequent fever, dry cough, and increase of inflammatory cytokines, and induced a mortality rate of 7.5%. Older patients or those with underlying comorbidities are at higher risk of death.
自 2019 年 12 月至 2020 年 2 月，2019 年严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在中国武汉引发了严重的 2019 年冠状病毒病（COVID-19）疫情。需要了解相关的临床特征。
我们回顾了 2020 年 1 月 16 日至 1 月 29 日期间在武汉协和医院住院的 69 例患者。所有患者均被证实感染了 SARS-CoV-2，随访的最终日期为 2020 年 2 月 4 日。
69 名入组患者的中位年龄为 42.0 岁（四分位距 35.0-62.0），32 名患者（46%）为男性。最常见的症状是发热（60[87%]）、咳嗽（38[55%]）和乏力（29[42%]）。大多数患者接受了抗病毒治疗（67[98.5%]例接受了抗病毒治疗）和抗生素治疗（67[98.5%]例接受了抗生素治疗）。截至 2020 年 2 月 4 日，67 例患者中有 18 例（26.9%）出院，5 例死亡，死亡率为 7.5%。根据入院期间最低 SpO2，病例分为 SpO2≥90%组（n=55）和 SpO2<90%组（n=14）。所有 5 例死亡均发生在 SpO2<90%组。与 SpO2≥90%组相比，SpO2<90%组患者年龄较大，合并症较多，白细胞介素（IL）6、IL10、乳酸脱氢酶和 C 反应蛋白水平较高。利巴韦林治疗有改善出院率和降低死亡率的趋势。
COVID-19 似乎表现为频繁发热、干咳和炎症细胞因子增加，并导致 7.5%的死亡率。年龄较大或有基础合并症的患者死亡风险较高。
